Cabot Medical
This article was originally published in The Gray Sheet
Executive Summary
Intends to take a charge of $8 mil. to $10 mil. in its fiscal fourth quarter related to "recent plans of the company to realign its operations to be more competitive" in the changing health care environment, the firm said Oct. 7. The charge will include reserves for potential severance packages, "reserves for product and facility rationalization, inventory and fixed asset reductions and other administrative cost reductions." The firm simultaneously announced that its Falope-Ring Band kit received FDA approval; additional information about the kit, used to perform tubal ligation sterilization procedures, will be released in the coming weeks.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.